Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07602582 · ClinicalTrials.gov registry record · Phase 3
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
A Phase 3 study, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 550
- Enrollment target
NCT07602582 is a Phase 3 study that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 550 participants.
The verdict
NCT07602582, a Phase 3 study, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 550 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.
Interventions
- DRUG Placebo
- DRUG Donanemab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2026-05-22 |
| Est. Completion | 2029-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07602582
The ClinicalTrials.gov registry entry for NCT07602582 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07602582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07602582 about?
NCT07602582 is a clinical study titled "A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).". The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.
What is the current status of trial NCT07602582?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 550 participants. The study started on 2026-05-22. Estimated completion is 2029-09.
What interventions are being tested in trial NCT07602582?
The interventions under investigation include: Placebo (DRUG), Donanemab (DRUG).
Who is sponsoring clinical trial NCT07602582?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.